GlobeNewswire

Align Technology Launches Treatment Planning Facility in Spain

Del

The newly opened facility will add 130 jobs in 2018, provide local support to Invisalign trained doctors in Spain and Portugal

MADRID, Spain and SAN JOSE, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDQ: ALGN), a global medical device company engaged in the design, manufacture and marketing of the Invisalign system and iTero intraoral scanners and services for orthodontic and restorative dentistry, announced today the launch of the new digital treatment planning facility and education centre in Madrid, Spain. The new launch reflects the dynamic growth of Spain and Portugal (jointly known as Iberia) in the EMEA region and beyond. Iberia is the third largest Invisalign market worldwide (after North America and China), growing dynamically year on year.

The second of its kind in Europe and the fourth worldwide, the treatment planning facility in Madrid aims to increase the company’s commitment to Invisalign trained doctors in Spain and Portugal, and will play a key role in Align Technology`s strategy to be closer to its customers and support them in digital treatment planning. The new facility, which will also act as education centre for doctors, will bring together current commercial teams representing Iberia and the new treatment planning team to provide Spanish and Portuguese doctors with first-hand support from the local staff. The new 3,500 square meter office will host 185 employees by the end of 2018 – a significant increase from the 10 employees employed in Spain since 2013.

“Since we launched our operations in the country 17 years ago, we have seen continuous growth and have played an important role in expanding Align’s operations in the EMEA region,” explained Juan Manuel Frade, Align Technology general manager, Iberia. “The city of Madrid offers a vibrant ecosystem for innovative companies, while our new facilities support Align`s efforts to offer first-hand local support to Spanish and Portuguese dental professionals, helping them achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients.”

The state-of-the-art facilities in Madrid will serve as commercial and operations site for the entire Iberia business. Align Technology, as a global medical company, works directly with doctors across both countries to provide them with the Invisalign system of clear aligners that doctors prescribe to their patients to straighten their teeth. The new facilities will provide Invisalign trained doctors with closer, more personalized support to ensure they in turn can offer improved service to their patients.

“Our newly opened facility in Madrid is an important step forward in bringing our technology closer to Invisalign doctors, in a time of growing demand for clear aligner therapy from both consumers and doctors,” said Emory Wright, senior vice president, global operations. This facility will allow us to directly support the orthodontists in Iberia in their effort to continue to achieve greater clinical outcomes in teeth straightening. The in-region expertise and localization of services in strategic markets is necessary for us to be able to serve the growing needs of the doctors for local support.”

The treatment planning facility will be equipped with the latest technology, including Align Technology’s proprietary software which makes it possible to create a customized treatment for each patient. The new treatment planning facilities are part of the 100 million dollar global investment that the company expects to make this year, and will enable the Madrid site to offer some of the most innovative orthodontic solutions in the region.

“We are extremely proud to be launching our second European treatment planning facility in Madrid. It spearheads the technological innovation within the clear aligner field, placing Spain and Portugal at the forefront of the digital future of orthodontics in Europe,” said Simon Beard, Align Technology senior vice president and managing director, EMEA. “Iberia continues dynamic business growth, being the strongest contributor to Align Technology’s 38% growth across EMEA last year. I am confident our expansion of the infrastructure and the geographical coverage will continue to deliver exceptional results and will help us strengthen our relations with Invisalign trained doctors in the region.”

The company officially opened the new facility today during a ceremony attended by Invisalign trained doctors from Spain, media and dental associations.

Clear aligners are a removable and transparent teeth-straightening solution produced using digital and 3D technologies. This type of solution differs from other orthodontic devices in that they are more comfortable and can be easily removed for eating or drinking. Used to treat minor to complex types of malocclusions, clear aligners are replaced every one or two weeks, depending on a doctor`s recommendation, gradually moving teeth towards the projected final position.

Digital treatments are created at Align Technology’s treatment planning facilities by CAD designers, following doctors’ guidelines and instructions. The new treatment planning facility represents a milestone in Align’s expansion in Iberia that will ensure that doctors in the region, which are already supported by local clinical and customer support teams, also benefit from the presence of local CAD designers, enabling doctors to offer an improved service to their own patients.

About Align Technology, Inc.

Align Technology is a global medical device company engaged in the design, manufacture and marketing the most advanced clear aligner system in the world and intraoral scanners and services for orthodontic and restorative dentistry. Align’s products help dental professionals achieve the clinical results they expect and deliver effective dental options to their patients. Visit www.aligntech.es or more information.

Media Contact:
Edelman
Oier Llinas
Oier.llinas@edelman.com
934881290

Karina Ludz
Align Technology
kludz@aligntech.com
+31 6211 434 20

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Bio-Fence announces a breakthrough in Food Safety18.1.2019 08:11Pressemelding

The company have successfully completed a field trial of its new anti-microbial coating technology. The trials demonstrated a significant reduction in bacterial contamination during sensitive food production processes ASHDOD, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Bio-Fence innovating coating technology announced today the successful completion of an intensive field trial on its innovative anti-microbial technology Pentagon. The trial was held in "Milouoff" (http://www.milouoff.co.il), one of the largest Ready to Eat poultry production sites in Israel and demonstrated superior results for Bio-Fence technology compared to alternatives. According to Mrs. Shiran Davidi, QA manager at Milouoff: “Bio-Fence technology seems to have clear benefits over existing antimicrobial solution. It is safe, highly potent and rechargeable.” The trial involved monitoring the performance of an epoxy floor coated with Bio-Fence anti-microbial technology compared to either commercial Silver Ion coating an

ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting18.1.2019 07:00Pressemelding

LYON, France and CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, announced that a poster entitled “TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)” will be presented today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in San Francisco. The poster (Abstract # TPS471) will be available at www.erytech.com after presentation at the conference. In September 2018, the TRYbeCA-1 trial was initiated. The Trial-in-Progress poster will provide an update on the study progress with investigators sites that have been initiated in multiple countries and actively recruiting patients. The trial is planned to enroll approximately 500 patients with

Fossil Group Enters Agreement To Sell Select Smartwatch Technology To Google17.1.2019 18:30Pressemelding

Transaction Unlocks Growth Opportunities for Fossil Group’s Wearables Business RICHARDSON, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Today, Fossil Group (NASDAQ:FOSL) announced its plan to sell to Google for $40 million intellectual property (IP) related to a smartwatch technology currently under development by Fossil Group. As part of the transaction, a portion of Fossil Group’s research and development (R&D) team currently supporting the transferring IP will join Google. Fossil Group retains more than 200 R&D team members to focus on innovation and product development. The transaction showcases Fossil Group and Google’s shared investment in the wearables industry. In recent years, smartwatches have become Fossil Group’s fastest growing category. The company successfully developed and launched smartwatches across 14 of its owned and licensed brands. “Fossil Group has experienced significant success in its wearables business by focusing on product design and development informed by our

Calgon Carbon Corporation Announces Global Price Increase17.1.2019 17:16Pressemelding

Pittsburgh, PA, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Calgon Carbon Corporation today announced a global price increase, effective February 1, 2019, where contracts permit, on all activated carbon products and related equipment due to a continued escalation in raw material costs and transportation expenses. The increase is expected to range between 10-15%, depending on the specific product, raw material type, services provided, and global market dynamics. The primary raw materials used for producing activated carbon are coal, coconut shell, and wood, each of which has gone up in price. Additionally, costs associated with both operating manufacturing facilities and transporting materials have also escalated. “Calgon Carbon’s raw material costs have increased significantly. Despite every effort to offset these increases through continuous improvements, the recent rise in raw material costs has exceeded our efforts,” said Jim Coccagno, Chief Commercial Officer for Calgon Carbon Corporation. “

Taconic Biosciences’ Animals Complete Most Recent Mission to the International Space Station17.1.2019 15:29Pressemelding

RENSSELAER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the completion of a recent mission to the International Space Station. This project represents a collaboration between the International Space Station (ISS) National Lab, National Aeronautics and Space Administration (NASA), Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. Taconic has participated in several spaceflight missions with NASA since 1985. Most recently, as part of the science and research investigation payloads supported by the SpaceX Commercial Resupply Services missions, Taconic prepared mice to live aboard the International Space Station for extended periods. Previous spaceflight studies demonstrated that mice undergo rapid loss of muscle and bone mass, resembling accelerated aging. Therefore, mice exposed to microgravity via spaceflight are a valuable model to understand and devel

MPP Global Bridges the Innovation Gap by Centralising Physical and Digital Subscriber Management and Billing in a Single Cloud Platform17.1.2019 12:29Pressemelding

WARRINGTON, UK, Jan. 17, 2019 (GLOBE NEWSWIRE) -- MPP Global, the technology company that delivers eSuite, the world’s smartest subscriber management & billing platform, announces the launch of pivotal new functionality which enables media organisations to seamlessly create and manage the sale of physical subscriptions. This positions eSuite as the complete physical and digital subscription management solution. The development of this industry-first functionality was borne out of the common challenge for publishers when managing multiple systems for deploying bundled print and digital subscriptions. This is inflexible for publishers and limits choice for their customers, restricting the ability to seamlessly create and offer digital and print subscription bundles. Despite increased consumer uptake of digital subscriptions, print still accounts for almost 90% of circulation revenues globally. To drive reader revenues successfully, publishers require functionality to execute complementar